Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression.
5-Hydroxytryptophan
/ administration & dosage
Animals
Constipation
/ drug therapy
Delayed-Action Preparations
/ administration & dosage
Depression
/ complications
Disease Models, Animal
Enteric Nervous System
/ drug effects
Female
Gastrointestinal Motility
/ drug effects
Gastrointestinal Tract
/ drug effects
Humans
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Mutation
Neurons
/ drug effects
Serotonin
/ metabolism
Treatment Outcome
Tryptophan Hydroxylase
/ genetics
CNS
GI Dysfunction
Gut–Brain Disease
Mood Disorders
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
10
12
2018
revised:
16
04
2019
accepted:
17
04
2019
pubmed:
10
5
2019
medline:
27
8
2019
entrez:
10
5
2019
Statut:
ppublish
Résumé
Mood disorders and constipation are often comorbid, yet their shared etiologies have rarely been explored. The neurotransmitter serotonin (5-HT) regulates central nervous system and enteric nervous system (ENS) development and long-term functions, including gastrointestinal (GI) motility and mood. Therefore, defects in neuron production of 5-HT might result in brain and intestinal dysfunction. Tryptophan hydroxylase 2 (TPH2) is the rate-limiting enzyme in 5-HT biosynthesis. A variant of TPH2 that encodes the R441H substitution (TPH2-R441H) was identified in individuals with severe depression. We studied mice with an analogous mutation (TPH2-R439H), which results in a 60%-80% decrease in levels of 5-HT in the central nervous system and behaviors associated with depression in humans. Feeding chow that contains 5-HTP slow release (5-HTP SR) to TPH2-R439H mice restores levels of 5-HT in the central nervous system and reduces depressive-like behaviors. We compared the effects of feeding chow, with or without 5-HTP SR, to mice with the TPH2-R439H mutation and without this mutation (control mice). Myenteric and submucosal plexuses were isolated from all 4 groups of mice, and immunocytochemistry was used to quantify total enteric neurons, serotonergic neurons, and 5-HT-dependent subsets of neurons. We performed calcium imaging experiments to evaluate responses of enteric neurons to tryptamine-evoked release of endogenous 5-HT. In live mice, we measured total GI transit, gastric emptying, small intestinal transit, and propulsive colorectal motility. To measure colonic migrating motor complexes (CMMCs), we isolated colons and constructed spatiotemporal maps along the proximodistal length to quantify the frequency, velocity, and length of CMMCs. We measured villus height, crypt perimeter, and relative densities of enterochromaffin and enteroendocrine cells in small intestinal tissue. Levels of 5-HT were significantly lower in enteric neurons from TPH2-R439H mice than from control mice. TPH2-R439H mice had abnormalities in ENS development and ENS-mediated GI functions, including reduced motility and intestinal epithelial growth. Total GI transit and propulsive colorectal motility were slower in TPH2-R439H mice than controls, and CMMCs were slower and less frequent. Villus height and crypt perimeter were significantly decreased in colon tissues from TPH2-R439H mice compared with controls. Administration of 5-HTP SR to adult TPH2-R439H mice restored 5-HT to enteric neurons and reversed these abnormalities. Adult TPH2-R439H mice given oral 5-HTP SR had normalized numbers of enteric neurons, total GI transit, and colonic motility. Intestinal tissue from these mice had normal measures of CMMCs and enteric epithelial growth CONCLUSIONS: In studies of TPH2-R439H mice, we found evidence for reduced release of 5-HT from enteric neurons that results in defects in ENS development and GI motility. Our findings indicate that neuron production of 5-HT links constipation with mood dysfunction. Administration of 5-HTP SR to mice restored 5-HT to the ENS and normalized GI motility and growth of the enteric epithelium. 5-HTP SR might be used to treat patients with intestinal dysfunction associated with low levels of 5-HT.
Sections du résumé
BACKGROUND & AIMS
Mood disorders and constipation are often comorbid, yet their shared etiologies have rarely been explored. The neurotransmitter serotonin (5-HT) regulates central nervous system and enteric nervous system (ENS) development and long-term functions, including gastrointestinal (GI) motility and mood. Therefore, defects in neuron production of 5-HT might result in brain and intestinal dysfunction. Tryptophan hydroxylase 2 (TPH2) is the rate-limiting enzyme in 5-HT biosynthesis. A variant of TPH2 that encodes the R441H substitution (TPH2-R441H) was identified in individuals with severe depression. We studied mice with an analogous mutation (TPH2-R439H), which results in a 60%-80% decrease in levels of 5-HT in the central nervous system and behaviors associated with depression in humans. Feeding chow that contains 5-HTP slow release (5-HTP SR) to TPH2-R439H mice restores levels of 5-HT in the central nervous system and reduces depressive-like behaviors.
METHODS
We compared the effects of feeding chow, with or without 5-HTP SR, to mice with the TPH2-R439H mutation and without this mutation (control mice). Myenteric and submucosal plexuses were isolated from all 4 groups of mice, and immunocytochemistry was used to quantify total enteric neurons, serotonergic neurons, and 5-HT-dependent subsets of neurons. We performed calcium imaging experiments to evaluate responses of enteric neurons to tryptamine-evoked release of endogenous 5-HT. In live mice, we measured total GI transit, gastric emptying, small intestinal transit, and propulsive colorectal motility. To measure colonic migrating motor complexes (CMMCs), we isolated colons and constructed spatiotemporal maps along the proximodistal length to quantify the frequency, velocity, and length of CMMCs. We measured villus height, crypt perimeter, and relative densities of enterochromaffin and enteroendocrine cells in small intestinal tissue.
RESULTS
Levels of 5-HT were significantly lower in enteric neurons from TPH2-R439H mice than from control mice. TPH2-R439H mice had abnormalities in ENS development and ENS-mediated GI functions, including reduced motility and intestinal epithelial growth. Total GI transit and propulsive colorectal motility were slower in TPH2-R439H mice than controls, and CMMCs were slower and less frequent. Villus height and crypt perimeter were significantly decreased in colon tissues from TPH2-R439H mice compared with controls. Administration of 5-HTP SR to adult TPH2-R439H mice restored 5-HT to enteric neurons and reversed these abnormalities. Adult TPH2-R439H mice given oral 5-HTP SR had normalized numbers of enteric neurons, total GI transit, and colonic motility. Intestinal tissue from these mice had normal measures of CMMCs and enteric epithelial growth CONCLUSIONS: In studies of TPH2-R439H mice, we found evidence for reduced release of 5-HT from enteric neurons that results in defects in ENS development and GI motility. Our findings indicate that neuron production of 5-HT links constipation with mood dysfunction. Administration of 5-HTP SR to mice restored 5-HT to the ENS and normalized GI motility and growth of the enteric epithelium. 5-HTP SR might be used to treat patients with intestinal dysfunction associated with low levels of 5-HT.
Identifiants
pubmed: 31071306
pii: S0016-5085(19)36715-0
doi: 10.1053/j.gastro.2019.04.022
pmc: PMC6650329
mid: NIHMS1527806
pii:
doi:
Substances chimiques
Delayed-Action Preparations
0
Serotonin
333DO1RDJY
5-Hydroxytryptophan
C1LJO185Q9
Tph2 protein, mouse
EC 1.14.16.4
Tryptophan Hydroxylase
EC 1.14.16.4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Pagination
507-521.e4Subventions
Organisme : NIMH NIH HHS
ID : R01 MH079201
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS015547
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK118971
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS102722
Pays : United States
Organisme : NIA NIH HHS
ID : T35 AG044303
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE026806
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK126644
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK093786
Pays : United States
Informations de copyright
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1333-8
pubmed: 18212115
J Neurosci. 2011 Jun 15;31(24):8998-9009
pubmed: 21677183
Brain Behav Immun. 2015 Aug;48:186-94
pubmed: 25882912
Gastroenterol Hepatol Bed Bench. 2011 Summer;4(3):159-63
pubmed: 24834176
Neuroscience. 1985 Sep;16(1):223-40
pubmed: 2940472
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
J Vis Exp. 2015 Jan 29;(95):
pubmed: 25741967
J Neurogastroenterol Motil. 2016 Apr 30;22(2):201-12
pubmed: 27032544
Psychoneuroendocrinology. 2006 May;31(4):473-84
pubmed: 16378695
J Neurogastroenterol Motil. 2017 Jul 30;23(3):349-362
pubmed: 28672433
J Affect Disord. 2018 Sep;237:37-46
pubmed: 29758449
Prim Care Companion J Clin Psychiatry. 2000 Dec;2(6):205-210
pubmed: 15014630
J Cell Mol Med. 2018 Mar;22(3):1778-1791
pubmed: 29314569
Neuropsychopharmacology. 2016 Aug;41(9):2324-34
pubmed: 26932820
Neuron. 2005 Jan 6;45(1):11-6
pubmed: 15629698
Mol Psychiatry. 2012 Jul;17(7):694-704
pubmed: 21537332
J Autoimmun. 1999 Dec;13(4):435-43
pubmed: 10585760
Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G419-28
pubmed: 16990446
Cell Host Microbe. 2015 May 13;17(5):565-76
pubmed: 25974299
J Affect Disord. 2017 Jan 01;207:300-304
pubmed: 27741466
Nat Rev Gastroenterol Hepatol. 2016 Sep;13(9):517-28
pubmed: 27435372
Proc Natl Acad Sci U S A. 2017 May 2;114(18):E3709-E3718
pubmed: 28420791
Gastroenterology. 2012 Aug;143(2):408-17.e2
pubmed: 22609381
Transl Psychiatry. 2013 Aug 13;3:e291
pubmed: 23942622
Physiol Rev. 1999 Oct;79(4):1089-125
pubmed: 10508230
Gut. 2014 Jun;63(6):928-37
pubmed: 23749550
J Clin Invest. 2016 Jun 1;126(6):2221-35
pubmed: 27111230
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):637-41
pubmed: 19272410
Neurogastroenterol Motil. 2011 Mar;23(3):233-9, e116
pubmed: 21073637
Curr Opin Endocrinol Diabetes Obes. 2013 Feb;20(1):14-21
pubmed: 23222853
NCHS Data Brief. 2018 Feb;(303):1-8
pubmed: 29638213
Mol Psychiatry. 2004 Nov;9(11):1030-6
pubmed: 15124006
Trends Pharmacol Sci. 2016 Nov;37(11):933-944
pubmed: 27692695
PLoS One. 2016 Dec 9;11(12):e0167055
pubmed: 27935995
Science. 2003 Jan 3;299(5603):76
pubmed: 12511643
Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2444-59
pubmed: 22826344
Gastroenterology. 2007 Jan;132(1):397-414
pubmed: 17241888
Eur Arch Psychiatry Clin Neurosci. 2014 Dec;264(8):651-60
pubmed: 24705634
Neurosci Lett. 1998 Jul 10;250(3):153-6
pubmed: 9708855
J Vis Exp. 2016 Feb 03;(108):53828
pubmed: 26862815
Can J Gastroenterol. 2011 Oct;25 Suppl B:11B-15B
pubmed: 22114752